ALT Insider Trading
Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): $52,000.00
Insider Selling (Last 12 Months): $110,475.90
Altimmune Share Price & Price History
Current Price: $5.92
Price Change: ▲ Price Increase of +0.72 (13.85%)
As of 03/14/2025 05:00 PM ET
Altimmune Insider Trading History
Altimmune Institutional Trading History
Data available starting January 2016
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Read More on Altimmune
Volume
12,149,179 shs
Average Volume
3,000,387 shs
Market Capitalization
$455.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.87
Who are the company insiders with the largest holdings of Altimmune?
Who are the major institutional investors of Altimmune?
Which institutional investors are selling Altimmune stock?
Within the previous quarter, ALT stock was sold by these institutional investors:
- Vanguard Group Inc.
- D. E. Shaw & Co. Inc.
- Exchange Traded Concepts LLC
- Squarepoint Ops LLC
- Schroder Investment Management Group
- Los Angeles Capital Management LLC
- BNP Paribas Financial Markets
- Valence8 US LP
Which institutional investors are buying Altimmune stock?
Within the previous quarter, ALT stock was bought by institutional investors including:
- Ameriprise Financial Inc.
- Invesco Ltd.
- Millennium Management LLC
- Two Sigma Investments LP
- Citadel Advisors LLC
- Ensign Peak Advisors Inc
- PEAK6 LLC
- Focus Partners Wealth
In the previous year, these company insiders have bought Altimmune stock:
- David Drutz (Director)
- Matthew Scott Harris (Insider)
- Gregory L Weaver (CFO)
Learn More investors buying Altimmune stock.